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Therapeutic Advances in Chronic Disease
Introduction
Ulcerative colitis (UC) and Crohn’s disease (CD) 
are chronic, relapsing inflammatory bowel dis-
eases (IBDs) [Lichenstein et al. 2008; Kornbluth 
et  al. 2010]. Differences between UC and CD 
include bowel wall involvement (mucosal versus 
transmural), patterns of inflammation (continu-
ous versus noncontinuous), location of inflamma-
tion (primarily rectum and colon versus entire 
gastrointestinal tract), and absence or presence of 
fistulas. Common symptoms for these diseases 
include diarrhea, abdominal tenderness or pain, 
rectal bleeding, and possible weight loss 
[Lichenstein et  al. 2008; Kornbluth et  al. 2010; 
Cosnes et  al. 2011; Danese et  al. 2014]. In the 
United States, the incidence and prevalence rates 
for UC and CD have been increasing and are 
reported as 7.9 and 8.8 cases per 100,000 person 
years and 263 and 241 per 100,000 adults diag-
nosed with UC and CD, respectively [Kappelman 
et al. 2013; Long et al. 2014].
The exact causes of UC and CD are unknown. 
Evidence suggests that environmental factors, 
genetic predisposition, and changes in the gastro-
intestinal microbial flora may trigger an overly 
aggressive immune response leading to elevations 
of proinflammatory mediators [e.g. interferon γ, 
certain interleukins and tumor necrosis factor α 
(TNF-α)] [Abrahm and Cho, 2009]. These medi-
ators recruit additional leukocytes, which results 
in a sustained inflammatory response and tissue 
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destruction [Abrahm and Cho, 2009; Zhang and 
Li, 2014]. Both UC and CD can be categorized 
as mild, moderate or severe, and characterized by 
exacerbations and remissions in most patients 
[Lichenstein et al. 2008; Kornbluth et al. 2010]. 
Treatment goals for patients with UC and CD 
include improving symptoms, inducing and main-
taining remission, and minimizing drug toxicities 
[Lichenstein et  al. 2008; Kornbluth et  al. 2010; 
D’Haens et al. 2014].
Conventional therapies for UC and CD target 
various cell mediators and include corticoster-
oids, aminosalicylates, immunomodulators, and 
monocolonal antibodies (Table 1) [Sharon et al. 
1978; Horn et al. 1991; Poldosky, 2002; Rousseaux 
et  al. 2005; Stolfi et  al. 2008; Kornbluth et  al. 
2010; Terdiman et  al. 2013; Marinkovic et  al. 
2014]. Over the years, TNF-α antagonists alone 
or in combination with other therapies have 
emerged as the cornerstone of treatment for 
induction and maintenance of remission of mod-
erate to severe UC and CD. Unfortunately, more 
than 60% of patients with UC and CD evaluated 
in clinical trials were unable to attain or maintain 
remission at week 52 after TNF-α antagonist 
initiation [Hanauer et  al. 2002; Rutgeerts et  al. 
2005; Colombel et al. 2007]. Moreover, it is docu-
mented that patients whose condition has failed 
to respond to one TNF-α antagonist have a mark-
edly reduced response rate when treated with a 
second TNF-α antagonist [Sandborn, 2007; 
Sandborn et al. 2007]. For these reasons, newer 
agents are needed to treat patients with moderate 
or severe UC or CD that is unresponsive, refrac-
tory, or patients who are unable to tolerate tradi-
tional treatment options.
The integrin receptor and vedolizumab
Integrin receptors have emerged as targets for 
newer therapies to treat patients with IBD. 
Integrins are composed of two subunits, α and β, 
and are found on certain B and T lymphocytes. At 
least 24 unique integrins have been identified in 
various combinations of α and β subunits. 
Although not exclusive, those associated with cell 
migration into the gastrointestinal tissue include 
α2β2, α4β1, and α4β7. By antagonizing these 
receptors there is inhibition of lymphocyte migra-
tion to the gastrointestinal mucosa during the 
inflammatory process [Gosh and Panaccione, 
2010; Jovani and Danese, 2013]. Natalizumab, 
the first integrin receptor antagonist approved by 
the US Food and Drug Administration (FDA), 
targets both the α4β1 and α4β7 integrins. Its ini-
tial US approval was for multiple sclerosis and 
later expanded to moderate to severe CD. Though 
deemed effective for CD, its use has been limited 
in this patient population because it can cause 
reactivation of the John Cunningham virus and 
possibly cause progressive multifocal leukoen-
cephalopathy (PML), a serious central nervous 
system infection that often results in mortality 
[Center for Drug Evaluation and Research, 2011; 
Biogen Idec Inc., 2013].
Vedolizumab (Entyvio; Takeda Pharmaceuticals, 
Deerfield, IL, USA), also known as MLN0002, is 
a humanized monoclonal antibody that selectively 
antagonizes α4β7 gastrointestinal integrin recep-
tors. It was approved by the FDA in May 2014, 
and is indicated for the treatment of patients with 
moderate to severe active UC and CD who have 
an inadequate response with, lost response to, or 
are intolerant to a TNF-α antagonist or an immu-
nomodulator; or have an inadequate response 
with, are intolerant to, or demonstrate depend-
ence on corticosteroids [Takeda Pharmaceuticals 
America Inc., 2014]. Because of vedolizumab’s 
receptor selectivity and improved safety profile 
over natalizumab, it is considered as a new treat-
ment option for patients with UC and CD. The 
purpose of this manuscript is to review the phar-
macology, pharmacokinetics, efficacy, adverse 
effects (AEs), drug–drug interactions, dosage and 
administration, cost, and place in therapy of 
vedolizumab.
Pharmacology
Vedolizumab is a humanized, anti-α4β7 integrin, 
monoclonal antibody [Takeda Pharmaceuticals 
America Inc., 2014]. The α4β7 integrin is a cell-
surface glycoprotein that is expressed on circulat-
ing B and T lymphocytes. It binds to adhesion 
molecules on gastrointestinal and other vascular 
endothelial cells to promote the influx of integrin 
binds specifically to the mucosal addressin cell 
adhesion molecule 1 and causes a decrease in 
gastrointestinal mucosal degradation and inflam-
mation [Erle et al. 1994; Fedyk et al. 2012].
Pharmacokinetics
Similar pharmacokinetic parameters of vedoli-
zumab have been reported in patients with UC 
and CD. In a dose-ranging study, 36 patients with 
UC were administered vedolizumab as a 30–60 
min intravenous infusion at doses of 2, 6, or 10 
Therapeutic Advances in Chronic Disease 6(5) 
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mg/kg at weeks 0, 2, and 4 (induction phase) and 
week 12 (maintenance phase). With each of these 
doses, maximum serum concentration and area 
under the curve were considered dose dependent. 
Serum concentrations declined in a linear manner 
when concentrations ranged from 1 to 10 μg/mL, 
with a nonlinear decline thereafter. Across all 
doses, the mean half-life ranged from 15–22 
days [Parikh et al. 2012]. These pharmacokinetic 
parameters were confirmed in phase III trials, 
when 300 mg of vedolizumab was administered 
as a 30 min intravenous infusion at weeks 0, 2, 6, 
and then every 4 or 8 weeks thereafter to patients 
with UC and CD. Trough serum concentrations 
declined in a linear fashion from week 6 to week 
46 from 26.3 to 11.2 μg/ml (UC) and from 27.4 
to 13 μg/ml (CD), and the serum half life was 
determined to be nearly 25 days. Further analysis 
of these data showed a linear clearance of 0.157 
L/day and a volume of distribution of approxi-
mately 5 L [Feagan et al. 2013; Sandborn et al. 
2013; Takeda Pharmaceuticals America Inc., 
2014].
Clinical efficacy
The FDA approval of vedolizumab for UC and 
CD was based on results from three prospective, 
randomized, multicenter, phase III trials 
(GEMINI 1, GEMINI 2, and GEMINI 3). 
GEMINI 1 and 2 were integrated trials with simi-
lar study design and methodology and consisted 
of both induction and maintenance studies for 
UC and CD, respectively, while GEMINI 3 was 
an induction only study for CD [Feagan et  al. 
2013; Sandborn et al. 2013; Sands et al. 2014]. In 
each of these trials, patients had moderate to 
severe disease (defined in Tables 2 and 3) with 
treatment failure to glucocorticoids and immu-
nomodulators (GEMINI 1, 2) or TNF-α inhibi-
tors (GEMINI 1, 2, 3). Each of these trials is 
summarized below and further detailed in Tables 
2 and 3 [Feagan et al. 2013; Sandborn et al. 2013; 
Sands et al. 2014].
Ulcerative colitis
GEMINI 1 evaluated the efficacy and safety of 
vedolizumab for induction and maintenance in 
895 adults with moderately to severely active UC 
[Feagan et  al. 2013]. The induction study was 
divided into two cohorts. In cohort 1 patients 
were randomized to intravenous vedolizumab 
300 mg (n = 225) or placebo (n = 149) at weeks 
0 and 2 while cohort 2 patients received open-
label vedolizumab 300 mg (n = 521) at the same 
time intervals. Patients from cohorts 1 and 2 who 
had a clinical response at week 6 (i.e. a 3-point or 
more reduction in the Mayo Clinic score and a 
30% or more reduction from the baseline score, 
along with a 1-point or more decrease on the rec-
tal bleeding subscale or a score of 0 or 1 for abso-
lute rectal bleeding) were allowed to move into 
the maintenance study. In this study patients 
were randomized to one of three treatment arms: 
intravenous vedolizumab 300 mg every 8 weeks, 
intravenous vedolizumab 300 mg every 4 weeks, 
or placebo. The primary efficacy endpoints for the 
induction and maintenance studies were clinical 
response at week 6 and clinical remission at 
week 52, respectively. Other outcomes assessed 
included durable clinical response and remission 
(both at weeks 6 and 52), mucosal healing, and 
corticosteroid-free remission (both at week 52). 
When reporting results, all endpoint differences 
were adjusted for concomitant use or no use of 
Table 1. Ulcerative colitis (UC) and Crohn’s disease 
(CD) therapies and proposed targets [Sharon et al. 
1978; Horn et al. 1991; Poldosky 2002; Rousseaux 
et al. 2005; Stolfi et al. 2008; Terdiman et al. 2013; 
Marinkovic et al. 2014].
Medications Proposed cell 
mediator targets
Corticosteroids COX-2, IL-1β, NF-
κB, IL-1β, PG  Budesonide
 Hydrocortisone  
 Methylprednisolone  
 Prednisone  
Aminosalicylates COX-2, IL-8, PPAR-
γ, PG, leukotrienes, 
NF-κB, TNF-α  
  
 Balsalazide
 Mesalamine
 Olsalazine
 Sulfasalazine
Immunomodulators Chemokines, IL-8
 6-Mercaptopurine
 Azathioprine
 Cyclosporine  
 Methotrexate  
TNF-α inhibitors TNF-α
 Adalimumab  
 Certolizumab pegol  
 Golimumab  
 Infliximab  
COX, cyclooxygenase; IL, interleukin; NF, nuclear factor; 
PG, prostaglandin; PPAR, peroxisome proliferator acti-
vated receptor; TNF, tumor necrosis factor.
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corticosteroids and concomitant use or prior use 
of immunomodulators or TNF-α antagonists. In 
the induction study, clinical response was achieved 
at week 6 by 47.1% of vedolizumab-treated 
patients compared with 25.5% of placebo-treated 
patients [adjusted difference 21.7%, 95% confi-
dence interval (CI) 11.6–31.7, p < 0.001, num-
ber needed to treat (NNT) = 4.6]. Other 
significant differences found between cohort 1 
groups at week 6 included the rate of clinical 
remission [vedolizumab (16.9%) versus placebo 
(5.4%); p = 0.001] and rate of mucosal healing 
[vedolizumab (40.9%) versus placebo (24.8%); p 
= 0.001]. For patients who received open-label 
vedolizumab (cohort 2), clinical response, remis-
sion, and mucosal healing rates were 44.3%, 
19.2%, and 36.7%, respectively. Of those who 
moved on to the maintenance study, vedolizumab-
treated patients had a better clinical remission 
compared with placebo-treated patients at week 
52 (every 8-week group: 41.8% versus 15.9%, 
adjusted difference 26.1%; 95% CI 14.9–37.2, p 
< 0.001, NNT = 3.8; and every 4-week group: 
44.8% versus 15.9%, adjusted difference 29.1%; 
95% CI 17.9–40.4, p < 0.001, NNT = 3.4). 
Additionally, patients who received vedolizumab 
every 8 weeks and every 4 weeks compared with 
placebo were more likely to achieve a durable 
clinical response (56.6% and 52% versus 23.8%, p 
< 0.001 and p < 0.001, respectively) durable 
clinical remission (20.5% and 24% versus 8.7%, p 
= 0.008 and p = 0.001, respectively), mucosal 
healing (51.6% and 56% versus 19.8%, p < 0.001 
and p < 0.001, respectively) and corticosteroid-
free remission (31.4% and 45.2% versus 13.9%, p 
= 0.01 and p < 0.001) at week 52. Limitations to 
this study exist. Unfortunately, the induction 
study only lasted 6 weeks. Extension of the induc-
tion study would have allowed for identifying the 
optimal time to induction instead of limiting it to 
the 6-week time period. Likewise, the minimal 
effective dose regimen was not determined since 
both regimens, though not directly compared, 
had similar efficacy. Finally, by using a placebo 
instead of an active comparator the exact place-
ment of vedolizumab in the treatment algorithm 
for the management of moderate to severe active 
UC is unknown.
Table 2. Summary of vedolizumab phase III studies in patients with active UC.
Reference Design Population Treatment Response endpoints
 Primary Secondary
GEMINI 1 
[Feagan  
et al. 2013]
R, parallel 
group, DB, 
PC
Moderate to 
severe UC* 
(n = 895)
Induction
Intravenous infusion 
on days 1, 15
C1R1: VDZ 300 mg 
(n = 225)
C1R2: PBO (n = 149)
C2: open label VDZ 
300 mg (n = 521)
Induction
Clinical response$ at 
week 6
47.1% C1R1 versus 
25.5% C1R2 (p < 
0.001)
44.3% C2
Induction
Clinical remission‡ at week 6
16.9% C1R1 versus 5.4% C1R2 
(p = 0.001)
19.2% C2
Mucosal healing§ at week 6
40.9% C1R1 versus 24.8% 
C1R2 (p = 0.001)
36.7% C2
 Maintenance
R1: VDZ every 8 
weeks (n = 122)
R2: VDZ every 4 
weeks (n = 125)
PBO (n = 126)
Maintenance
Clinical remission‡ at 
week 52
41.8% R1 and 44.8% 
R2 versus 15.9% PBO 
(p < 0.001 and p < 
0.001, respectively)
Maintenance
Mucosal healing§ at week 52
51.6% R1 and 56% R2 versus 
19.8% PBO (p < 0.001 and p < 
0.001, respectively)
Glucocorticoid-free remission‖
31.4% R1 and 45.2% R2 versus 
13.9% PBO (p = 0.01 and p < 
0.001, respectively)
*Moderate to severe active disease: baseline Mayo Clinical Score (MCS) of at least 6 points and endoscopy subscore of at least 2 points.
$Clinical response: decrease of at least 3 points in MCS and decrease of at least 30% of baseline MCS, with a decrease of at least 1 point on the 
rectal bleeding subscale or a score of 0 or 1 for absolute rectal bleeding.
‡Clinical remission: MCS up to 2 points with no subscore greater than 1 point.
§Mucosal healing: score of 0 or 1 for endoscopic subscore.
‖Glucocorticoid-free remission assessed in patients receiving oral corticosteroids at baseline.
DB, double blind; C1R1, cohort 1 regimen 1; C1R2, cohort 1 regimen 2; C2, cohort 2; PBO, placebo; PC, placebo controlled, R, randomized; R1, 
regimen 1; R2, regimen 2; VDZ, vedolizumab.
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Crohn’s disease
GEMINI 2 assessed the efficacy and safety of 
vedolizumab for induction and maintenance in 
1115 adults with moderate to severe active CD 
[Sandborn et al. 2013]. Similar to GEMINI 1, the 
induction study consisted of two cohorts. In 
cohort 1 patients were randomized to intravenous 
vedolizumab 300 mg (n = 220) or placebo (n = 
148) at weeks 0 and 2 while patients in cohort 2 
received open-label vedolizumab 300 mg (n = 
747) also at weeks 0 and 2. All patients from 
cohorts 1 and 2 moved onto the maintenance 
phase and were followed through week 52, yet 
they were divided into two groups based on clini-
cal response [i.e. ⩾70-point reduction in the CD 
Activity Index (CDAI) at week 6]. Patients who 
were considered ‘clinical responders’ were rand-
omized equally to vedolizumab 300 mg every 8 
Table 3. Summary of vedolizumab phase III studies in patients with active Crohn’s disease (CD).
Reference Design Population Treatment Response endpoints
 Primary Secondary
GEMINI 2 
[Sandborn 
et al. 2013]
R, parallel 
group, DB, 
PC
Moderate to 
severe CD*
(n = 1115)
Induction
Intravenous infusion 
on weeks 0, 2
C1R1: VDZ 300 mg (n 
= 220)
C1R2: PBO (n = 148)
C2: open label VDZ 
300 mg (n = 747)
Induction
Clinical remission† at 
week 6
14.5% C1R1 vs. 6.8% 
C1R2, p = 0.02
17.7% C2
CDAI-100 response‡ 
at week 6
31.4% C1R1 vs. 25.7% 
C1R2, p = 0.23
34.4% C2
 
 Maintenance
R1: VDZ every 8 
weeks (n = 154)
R2: VDZ every 4 
weeks (n = 154)
PBO (n = 153)
Maintenance
Clinical remission$ at 
week 52
39% R1 and 36.4% R2 
versus 21.6% PBO
17.4, p < 0.001 and
14.8, p = 0.004, 
respectively
Maintenance
CDAI-100 response‡ at  
week 52
43.5% R1 and 45.5% R2 versus 
30.1% PBO
13.4, p = 0.01 and
15.4, p = 0.005, respectively
Glucocorticoid-free remission§
31.7% R1 and 28.8% R2 versus 
15.9% PBO
15.8, p = 0.02 and
12.9, p = 0.04, respectively
GEMINI 
3 [Sands 
et al. 2014]
R, DB, PC Moderate to 
severe CD*
(n = 416)
Intravenous infusion 
on weeks 0, 2, 6
VDZ 300 mg (n = 209)
PBO (n = 207)
TNF-α antagonist 
failure population
Clinical remission$ at 
week 6
15.2% VDZ versus 
12.1% PBO
3.0 (95% CI −4.5 to 
10.5), p = 0.433
TNF-α antagonist failure 
population
CDAI-100 response‡ at week 6
39.2% VDZ versus 22.3% PBO
16.9 (95% CI 6.7–27.1), p = 0.001
Clinical remission$ at week 10
26.6% VDZ versus 12.1% PBO
14.4 (95% CI 5.7–23.1), p = 0.001
Overall population
Clinical remission† at week 6
19.1% VDZ versus 12.1% PBO
6.9 (95% CI 0.1–13.8), p = 0.048
Clinical remission$ at week 10
28.7% VDZ versus 13.0% PBO
15.5 (95% CI 7.8–23.3), p < 0.0001
*Moderate to severe active disease: CD Activity Index (CDAI) score of 220–450.
$Clinical remission: CDAI score up to 150 points.
‡CDAI-100 response: decrease of at least 100 points in CDAI score.
§Glucocorticoid-free remission: clinical remission without corticosteroids at week 52.
C1R1, cohort 1 regimen 1; C1R2, cohort 1 regimen 2; C2, cohort 2; CI, confidence interval; DB, double blind; PBO, placebo; PC, placebo controlled; 
R, randomized; R1, regimen 1; R2, regimen 2; VDZ, vedolizumab.
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weeks, vedolizumab 300 mg every 4 weeks, or pla-
cebo, while those who were considered ‘clinical 
nonresponders’ received vedolizumab 300 mg 
every 4 weeks. The primary efficacy outcomes 
for these studies were clinical remission (CDAI 
score ⩽ 150 points) and CDAI-100 response 
(⩾100-point decrease in the CDAI score) at 
week 6 (induction) and clinical remission at 
week 52 (maintenance). Secondary outcomes 
measured at week 6 for the induction study were 
a change in mean C-reactive protein levels from 
baseline and at week 52 for the maintenance 
study, a CDAI-100 response, glucocorticoid-
free remission (i.e. no corticosteroid at week 52 
use while in clinical remission), and durable 
clinical remission (i.e. clinical remission at 80% 
or more of study visits that included the final 
visit). In cohort 1 of the induction study, more 
patients receiving vedolizumab treatment 
achieved clinical remission at week 6 compared 
with patients receiving placebo (14.5% versus 
6.8%, p = 0.02, respectively). However, no 
significant difference in CDAI-100 response 
[vedolizumab (31.4%) versus placebo (25.7%); 
p = 0.23] or changes in mean C-reactive protein 
levels from baseline were detected at week 6. Of 
the patients in cohort 2, 17.7% (132/747) 
achieved clinical remission and 34.4% (257/747) 
had a CDAI-100 response at week 6. In the 
maintenance study, a greater percentage of 
patients who received vedolizumab achieved 
clinical remission at week 52 [every 8 weeks 
(39.0%), every 4 weeks (36.4%) compared with 
placebo (21.6%), p < 0.001 and p = 0.004, 
respectively]. Additionally, when patients who 
received vedolizumab treatment were compared 
with those receiving placebo there was a signifi-
cant difference between groups for CDAI-100 
response [every 8 weeks (43.5%), every 4 weeks 
(45.5%), placebo (30.1%); p = 0.01 and p = 
0.005, respectively] and glucocorticoid-free 
remission [every 8 weeks (31.7%), every 4 weeks 
(28.8%), placebo (15.9%), p = 0.02 and p = 
0.04, respectively]. There was no difference 
between groups for durable clinical remission. 
This study may be limited by its study popula-
tion. The majority of enrolled patients had 
extremely refractory and complicated disease 
with nearly half of patients having a history of 
surgery or fistulizing disease and 15% of patients 
having active, draining fistulas at enrollment. 
This population has not been included in previ-
ous trials with TNF-α inhibitors and may have 
confounded the response rates reported for 
vedolizumab.
In an effort to examine subpopulations that may 
benefit from vedolizumab therapy in active 
CD, the GEMINI 3 study was conducted to 
determine the efficacy of vedolizumab induction 
specifically in those with moderately or severely 
active CD whose condition previously failed to 
respond to TNF-α antagonists [Sands et  al. 
2014]. Patients were randomized to receive 
intravenous vedolizumab 300 mg (n = 209) or 
placebo (n = 207) at weeks 0, 2, and 6. 
Randomization was stratified based on previous 
TNF-α antagonist status, concomitant corticos-
teroid use, and concomitant immunosuppressive 
use. The majority of patients (76%, 315/416) 
had disease that failed to respond to previous 
TNF-α antagonist therapy and this was consid-
ered the primary efficacy analysis population. 
The primary efficacy outcome was clinical 
remission (CDAI ⩽ 150 points) at week 6 in 
patients whose condition failed to respond to 
prior TNF-α antagonist treatment. Secondary 
efficacy outcomes for the TNF-α antagonist fail-
ure population included CDAI-100 response 
(⩾100-point decrease from baseline in CDAI) at 
week 6 and clinical remission at week 10 and for 
the overall population included clinical remis-
sion at weeks 6 and 10. There was no significant 
difference between treatment groups for the pro-
portion of patients achieving clinical remission 
at week 6 [vedolizumab (15.2%) versus placebo 
(12.1%); p = 0.433]. Since the primary outcome 
was not statistically significant, analysis of 
secondary outcomes was only completed for char-
acterization purposes. In the TNF-α antagonist-
failure population, patients who received 
vedolizumab treatment had a greater CDAI-100 
response compared with placebo at week 6 
(39.2% versus 22.3%, p = 0.001) and clinical 
remission was achieved in more patients treated 
with vedolizumab at week 10 compared with 
those receiving placebo (26.6% versus 12.1%, 
p = 0.001). In the overall population, a greater 
proportion of patients who received vedolizumab 
achieved clinical remission at week 6 [vedoli-
zumab (19.1%) versus placebo (12.1%); p = 
0.048] and at week 10 [vedolizumab (28.7%) 
versus placebo (13.0%); p < 0.0001]. Despite 
the insignificant results of the primary efficacy 
outcome, the authors state that the collective 
primary and secondary results suggest that the 
full effects of vedolizumab on clinical remission 
may not be realized until after week 6 of treat-
ment, specifically in patients whose condition 
failed to respond to prior TNF-α antagonist 
therapy.
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Other clinical trials evaluating vedolizumab in 
adults with moderate or severe active UC or CD 
are ongoing. Two of these trials are designed to 
assess clinical response and clinical remission at 
longer time periods than the previously published 
trials (i.e. induction therapy at week 10 and main-
tenance at week 60). One trial (GEMINI LTS) 
is focusing on long-term safety (i.e. up to 7 
years) and another trial is evaluating vedolizumab 
when administered as a subcutaneous injection 
[ClinicalTrials.gov identifiers: NCT00790933, 
NCT02038920, NCT02039505, NCT0216342].
Adverse effects
Vedolizumab is generally well tolerated with an 
AE profile and tolerability being relatively similar 
among trials. AEs reported in 10% or more of 
patients receiving vedolizumab in these trials 
include upper respiratory infection, nasopharyngi-
tis, abdominal pain, nausea, CD exacerbation, 
arthralgia, pyrexia, and headache [Feagan et  al. 
2013; Sandborn et al. 2013; Sands et al. 2014]. In 
the GEMINI 1 study, the incidence of serious AEs 
did not differ from placebo (12.4% versus 13.5%, 
respectively); however, in GEMINI 2, there was a 
higher incidence of serious infections and malig-
nancies reported in patients receiving vedolizumab 
compared with those on placebo (serious infec-
tions: 5.5% versus 3.0%, respectively; and malig-
nancies: 0.5% versus 0.3%, respectively) [Feagan 
et  al. 2013; Sandborn et  al. 2013; Takeda 
Pharmaceuticals America Inc., 2014]. Infusion-
related reactions (up to 4% of patients) have been 
reported with vedolizumab administration. The 
most common infusion-related reaction symp-
toms include nausea, headache, pruritus, dizzi-
ness, fatigue, pyrexia, urticaria, and vomiting. 
Anaphylaxis has rarely (i.e. one patient in clinical 
trials) been reported with vedolizumab [Takeda 
Pharmaceuticals America Inc., 2014].
PML
More than 3000 patients received vedolizumab in 
clinical studies for a median of 313 days with no 
cases of PML reported [ClinicalTrials.gov identi-
fier: NCT00790933; Feagan et al. 2013; Sandborn 
et  al. 2013; Sands et  al. 2014]. Prior to FDA 
approval, an independent adjudication committee 
of the FDA conducted a risk assessment and min-
imization for the association of PML with vedoli-
zumab and no cases of PML were identified 
[FDA, 2013]. Thus, vedolizumab was FDA 
approved without a risk evaluation minimization 
strategy. However, to ensure patient safety, the 
manufacturer of vedolizumab must conduct a 
prospective, observational cohort study that com-
pares vedolizumab with other treatments for IBD 
with a primary outcome of serious infections and 
secondary outcomes including PML. The 
expected completion date for the study is 2021 
[Gingery, 2014]. Additionally, an open-label 
phase III trial to determine the long-term safety 
of vedolizumab in patients with UC and CD 
(GEMINI LTS), with safety evaluations includ-
ing PML, is ongoing and due to be completed in 
March 2016 [ClinicalTrials.gov identifier: 
NCT00790933].
Immunogenicity
An early formulation of vedolizumab (MLN002) 
was derived from mouse myeloma cell lines and 
caused human anti-human antibodies (HAHA) 
development in up to 44% of patients [Feagan 
et  al. 2005; Parikh et  al. 2012]. In an effort to 
reduce immunogenicity, a new formulation of 
vedolizumab derived from a Chinese hamster 
ovary cell based system was developed [Parikh 
et al. 2012]. This new formulation was evaluated 
in the GEMINI 1, 2, and 3 studies and resulted 
in 1–4.1% of patients being positive for anti- 
vedolizumab antibodies at any time point and 
0.4–1% of patients being persistently positive 
throughout the trials [Feagan et al. 2013; Sandborn 
et al. 2013; Sands et al. 2014].
Drug–drug interactions
Concomitant administration of vedolizumab with 
TNF-α antagonists and natalizumab should be 
avoided because of increased infection risk and 
PML, respectively. Additionally, live vaccines 
should only be given to patients receiving vedoli-
zumab if the benefit clearly outweighs the risk 
[Takeda Pharmaceuticals America Inc., 2014].
Dosing and administration
Before starting vedolizumab therapy, patients 
should be considered for tuberculosis screening, 
have baseline liver enzyme tests drawn, and 
brought up to date with all routine vaccinations. 
If vaccinations need to be given while a patient is 
receiving vedolizumab then inactivated vaccines 
may be given when indicated (though lower sero-
conversion rates may or may not occur), yet live 
vaccines should only be given after risk–benefit 
considerations. To date, no reports of secondary 
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transmission of infection by live vaccines in 
patients receiving vedolizumab exist [Takeda 
Pharmaceuticals America Inc., 2014].
Initial dose-finding studies for vedolizumab used 
weight-based dosing with doses ranging from 
0.15 to 10 mg/kg administered as single doses or 
at different dosing intervals (e.g. weeks 0 and 4 or 
weeks 0, 2, 4, and 12) [Feagan et al. 2000, 2005, 
2008; Parikh et  al. 2012]. In phase III trials, 
vedolizumab dosing was standardized to a 300 
mg intravenous infusion given at weeks 0, 2, for 
induction and then every 4 or 8 weeks for mainte-
nance. This standardized dose corresponded to a 
mean dose of 4.1 mg/kg (UC) and 4.3 mg/kg 
(CD), with induction primarily achieved by week 
6 and similar clinical outcomes when mainte-
nance doses were given every 4 or 8 weeks [Feagan 
et al. 2013; Sandborn et al. 2013]. These results 
led to the FDA-approved dosing regimen of 300 
mg as a 30 min intravenous infusion on weeks 0, 
2, and 6, and then every 8 weeks thereafter for 
both UC and CD [Takeda Pharmaceuticals 
America Inc., 2014]. Product labeling recom-
mends that vedolizumab treatment be discontin-
ued if patients do not show signs of response by 
week 14 [Takeda Pharmaceuticals America Inc., 
2014].
Due to the risk of hypersensitivity reactions, 
including anaphylaxis, vedolizumab must be 
administered by a healthcare provider equipped 
to respond to such reactions. Additionally, 
patients must be monitored for these possible 
infusion-type reactions throughout the 30 min 
infusion period [Takeda Pharmaceuticals America 
Inc., 2014]. If patients have a non-life-threatening 
infusion reaction history then administration of 
acetaminophen, antihistamines, or corticoster-
oids should be considered before the start of the 
infusion [Takeda Pharmaceuticals America Inc., 
2014]. However, if a serious hypersensitivity 
reaction occurs during vedolizumab administra-
tion, vedolizumab should be immediately discon-
tinued and medications for treating the reaction 
administered to the patient (e.g. epinephrine, 
antihistamines, corticosteroids).
Cost considerations
The average wholesale cost of a 300 mg vial of 
vedolizumab in the US is $5782.80 [The Redbook 
(On Line), 2014]. Based on the recommended 
dosing of 300 mg on weeks 0, 2, 6, and then every 
8 weeks thereafter, the cost of vedolizumab for the 
initial year of treatment is approximately $52,000 
and for subsequent years approximately $34,700. 
To account for individual drug reimbursement, 
vedolizumab should generally be administered in 
an outpatient infusion clinic setting. The manu-
facturer of vedolizumab does provide support for 
copayment assistance for those with private insur-
ance, identification of independent patient sup-
port foundations for possible financial assistance 
for those with Medicare/Medicaid, and determi-
nation of patient assistance qualification for those 
without insurance [Entyvio Connect, 2015]. To 
date, cost-effectiveness analyses comparing ved-
olizumab with other therapies approved for UC 
and CD have not been performed.
Conclusion
Vedolizumab is an α4β7 integrin antagonist 
approved for use in patients with moderate to 
severe UC or CD who are considered non-
responders, have relapsing disease, or are unable 
to tolerate TNF-α antagonists or who or have an 
inadequate response with, are intolerant to, or 
demonstrate dependence on corticosteroids. 
When administered according to approved dosing 
in patient with moderate to severe CD and UC, 
vedolizumab induces clinical response rates up to 
31.4% and 47.1% at week 6 and clinical remis-
sion rates at week 52 up to 39% and 41.8%. 
Unlike other FDA approved integrin antagonists, 
vedolizumab is gastrointestinal selective and has 
not shown evidence of causing PML; however, 
postmarketing studies are ongoing to ensure 
patient safety for this serious AE. Other serious 
AEs reported in trials with vedolizumab include 
serious infections, malignancies, and anaphylaxis. 
Further assessment of vedolizumab earlier in the 
course of these diseases and in combination with 
other therapies is warranted.
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